Do Analysts Expect Lineage Cell Therapeutics Inc (LCTX) Stock to Rise After It Is Higher By 1.42% in a Month?

Wall Street is positive on Lineage Cell Therapeutics Inc (LCTX). On average, analysts give Lineage Cell Therapeutics Inc a Strong Buy rating. The average price target is $6.75, which means analysts expect the stock to increase by 372.03% over the next twelve months. That average ranking earns Lineage Cell Therapeutics Inc an Analyst Rating of 59, which is better than 59% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating LCTX a Strong Buy today. Find out what this means to you and get the rest of the rankings on LCTX!

See Full LCTX Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Lineage Cell Therapeutics Inc Stock Today?

Lineage Cell Therapeutics Inc (LCTX) stock is trading at $1.43 as of 2:56 PM on Thursday, Mar 24, a rise of $0.05, or 3.62% from the previous closing price of $1.38. The stock has traded between $1.37 and $1.45 so far today. Volume today is 461,151 compared to average volume of 543,136. Click Here to get the full Stock Report for Lineage Cell Therapeutics Inc stock.